Drug Overview
Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.
It has also been hypothesized that blocking the PD-1/PD-L1 interaction may preferentially release the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.
Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.
It has also been hypothesized that blocking the PD-1/PD-L1 interaction may preferentially release the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.
Table of Contents
OVERVIEW
- Drug Overview
- Product Profiles
- Keytruda : Hepatocellular carcinoma (HCC)
- Keytruda : Renal cell carcinoma (RCC)
- Keytruda : NHL: Diffuse large B-cell lymphoma (DLBCL)
- Keytruda : Non-small cell lung cancer (NSCLC)
- Keytruda : Melanoma
- Keytruda : Gastric cancer
- Keytruda : Colorectal cancer (CRC)
- Keytruda : Head and neck cancer
- Keytruda : Bladder cancer
- Keytruda : Breast cancer: triple-negative
LIST OF FIGURES
Figure 1: The author's drug assessment summary of Keytruda for HCC
Figure 2: The author's drug assessment summary of Keytruda for HCC
Figure 3: Keytruda sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 4: Keytruda for RCC – SWOT analysis
Figure 5: The author's drug assessment summary of Keytruda for RCC
Figure 6: The author's drug assessment summary of Keytruda for RCC
Figure 7: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Keytruda for diffuse large B-cell lymphoma – SWOT analysis
Figure 9: The author's drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 10: The author's drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 11: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Keytruda for non-small cell lung cancer – SWOT analysis
Figure 13: The author's drug assessment summary for Keytruda in non-small cell lung cancer
Figure 14: The author's drug assessment summary for Keytruda in non-small cell lung cancer
Figure 15: Keytruda sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 16: Keytruda in melanoma – SWOT analysis
Figure 17: The author's drug assessment summary of Keytruda for melanoma
Figure 18: The author's drug assessment summary of Keytruda for melanoma
Figure 19: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Keytruda for gastric cancer – SWOT analysis
Figure 21: The author's drug assessment summary of Keytruda for gastric cancer
Figure 22: The author's drug assessment summary of Keytruda for gastric cancer
Figure 23: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Keytruda for colorectal cancer – SWOT analysis
Figure 25: The author's drug assessment summary for Keytruda in colorectal cancer
Figure 26: The author's drug assessment summary for Keytruda in colorectal cancer
Figure 27: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 28: Keytruda for head and neck cancer – SWOT analysis
Figure 29: The author's drug assessment summary of Keytruda for SCCHN
Figure 30: The author's drug assessment summary of Keytruda for SCCHN
Figure 31: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Figure 32: Keytruda for urothelial bladder cancer – SWOT analysis
Figure 33: The author's drug assessment summary for Keytruda in urothelial bladder cancer
Figure 34: The author's drug assessment summary for Keytruda in urothelial bladder cancer
Figure 35: Keytruda for triple-negative breast cancer – SWOT analysis
Figure 36: The author's drug assessment summary of Keytruda for triple-negative breast cancer
Figure 37: The author's drug assessment summary of Keytruda for triple-negative breast cancer
Figure 2: The author's drug assessment summary of Keytruda for HCC
Figure 3: Keytruda sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 4: Keytruda for RCC – SWOT analysis
Figure 5: The author's drug assessment summary of Keytruda for RCC
Figure 6: The author's drug assessment summary of Keytruda for RCC
Figure 7: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Keytruda for diffuse large B-cell lymphoma – SWOT analysis
Figure 9: The author's drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 10: The author's drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 11: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Keytruda for non-small cell lung cancer – SWOT analysis
Figure 13: The author's drug assessment summary for Keytruda in non-small cell lung cancer
Figure 14: The author's drug assessment summary for Keytruda in non-small cell lung cancer
Figure 15: Keytruda sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 16: Keytruda in melanoma – SWOT analysis
Figure 17: The author's drug assessment summary of Keytruda for melanoma
Figure 18: The author's drug assessment summary of Keytruda for melanoma
Figure 19: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Keytruda for gastric cancer – SWOT analysis
Figure 21: The author's drug assessment summary of Keytruda for gastric cancer
Figure 22: The author's drug assessment summary of Keytruda for gastric cancer
Figure 23: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Keytruda for colorectal cancer – SWOT analysis
Figure 25: The author's drug assessment summary for Keytruda in colorectal cancer
Figure 26: The author's drug assessment summary for Keytruda in colorectal cancer
Figure 27: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 28: Keytruda for head and neck cancer – SWOT analysis
Figure 29: The author's drug assessment summary of Keytruda for SCCHN
Figure 30: The author's drug assessment summary of Keytruda for SCCHN
Figure 31: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Figure 32: Keytruda for urothelial bladder cancer – SWOT analysis
Figure 33: The author's drug assessment summary for Keytruda in urothelial bladder cancer
Figure 34: The author's drug assessment summary for Keytruda in urothelial bladder cancer
Figure 35: Keytruda for triple-negative breast cancer – SWOT analysis
Figure 36: The author's drug assessment summary of Keytruda for triple-negative breast cancer
Figure 37: The author's drug assessment summary of Keytruda for triple-negative breast cancer
LIST OF TABLES
Table 1: Recent high-impact events for Keytruda in HCC
Table 2: Keytruda drug profile
Table 3: Approval history of Keytruda for HCC in the US, Japan, and five major EU markets
Table 4: Trials of Keytruda for HCC
Table 5: Keytruda for HCC – SWOT analysis
Table 6: Keytruda drug profile
Table 7: Keytruda Phase III data in RCC
Table 8: Keytruda Phase III trials in RCC
Table 9: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Keytruda drug profile
Table 11: Keytruda pivotal trial data in diffuse large B-cell lymphoma
Table 12: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: Keytruda drug profile
Table 14: Keytruda pivotal trial data in non-small cell lung cancer
Table 15: Keytruda ongoing late-phase clinical trials in non-small cell lung cancer
Table 16: Keytruda sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 17: Keytruda patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 18: Keytruda drug profile
Table 19: Keytruda pivotal trial data in melanoma
Table 20: Keytruda ongoing clinical trials in melanoma
Table 21: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 22: Keytruda patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
Table 23: Keytruda drug profile
Table 24: Keytruda pivotal trial data in gastric cancer
Table 25: Keytruda Phase III trials in gastric cancer
Table 26: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 27: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Table 28: Keytruda drug profile
Table 29: Keytruda Phase III trial in colorectal cancer
Table 30: Keytruda early-phase data in colorectal cancer
Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
Table 33: Keytruda drug profile
Table 34: Keytruda pivotal trial data in head and neck cancer
Table 35: Keytruda ongoing late-phase trials in head and neck cancer
Table 36: Keytruda early-phase data in head and neck cancer
Table 37: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 38: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Table 39: Keytruda drug profile
Table 40: Keytruda pivotal trial data in urothelial bladder cancer
Table 41: Keytruda ongoing late-phase trials in urothelial bladder cancer
Table 42: Keytruda early-phase data in urothelial bladder cancer
Table 43: Keytruda drug profile
Table 44: Keytruda Phase III trial in triple-negative breast cancer
Table 45: Keytruda Phase Ib data in triple-negative breast cancer
Table 2: Keytruda drug profile
Table 3: Approval history of Keytruda for HCC in the US, Japan, and five major EU markets
Table 4: Trials of Keytruda for HCC
Table 5: Keytruda for HCC – SWOT analysis
Table 6: Keytruda drug profile
Table 7: Keytruda Phase III data in RCC
Table 8: Keytruda Phase III trials in RCC
Table 9: Keytruda sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Keytruda drug profile
Table 11: Keytruda pivotal trial data in diffuse large B-cell lymphoma
Table 12: Keytruda sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: Keytruda drug profile
Table 14: Keytruda pivotal trial data in non-small cell lung cancer
Table 15: Keytruda ongoing late-phase clinical trials in non-small cell lung cancer
Table 16: Keytruda sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 17: Keytruda patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 18: Keytruda drug profile
Table 19: Keytruda pivotal trial data in melanoma
Table 20: Keytruda ongoing clinical trials in melanoma
Table 21: Keytruda sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 22: Keytruda patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
Table 23: Keytruda drug profile
Table 24: Keytruda pivotal trial data in gastric cancer
Table 25: Keytruda Phase III trials in gastric cancer
Table 26: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 27: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Table 28: Keytruda drug profile
Table 29: Keytruda Phase III trial in colorectal cancer
Table 30: Keytruda early-phase data in colorectal cancer
Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
Table 33: Keytruda drug profile
Table 34: Keytruda pivotal trial data in head and neck cancer
Table 35: Keytruda ongoing late-phase trials in head and neck cancer
Table 36: Keytruda early-phase data in head and neck cancer
Table 37: Keytruda sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 38: Keytruda patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
Table 39: Keytruda drug profile
Table 40: Keytruda pivotal trial data in urothelial bladder cancer
Table 41: Keytruda ongoing late-phase trials in urothelial bladder cancer
Table 42: Keytruda early-phase data in urothelial bladder cancer
Table 43: Keytruda drug profile
Table 44: Keytruda Phase III trial in triple-negative breast cancer
Table 45: Keytruda Phase Ib data in triple-negative breast cancer
